Aurora Cannabis (ACB): A Real Lift or a Dead Cat Bounce?

    2 Apr by Vitaliy Dadalyan Tags:

    Aurora Cannabis (ACB): A Real Lift or a Dead Cat Bounce?

    In mid-March, Aurora Cannabis (ACB) hit a 52-week low of $0.60 per share, with some commentators believing it hadn't hit bottom yet. While it appears a bottom is in, the question going forward is whether or not the company can hold on to some of its recent gains.After hitting its bottom, a little over a week later the company soared to over $1.13 per share, pulling back to $0.85 per share as I write.In this article we'll look at whether or not the company will be able to sustain or increase these gains, and what it would take to do so.The key factor in the near termWithout a doubt the key to short-term growth for Aurora is recreational sales in Canada. If it is able to do well there, it will surprise the market to the upside and give its share price another boost that would have a good chance to...
    2 Apr by Vitaliy Dadalyan Tags:

    Trump says he brokered deal with Saudi, Russia for huge oil cuts

    U.S President Donald Trump said on Thursday he had brokered a deal with top oil producers Russia and Saudi Arabia to cut output and arrest an oil price rout amid a global coronavirus pandemic, sending crude prices up by 45%. Trump said he spoke with Russian President Vladimir Putin and Saudi Crown Prince Mohammed bin Salman, and now expected the two nations to cut output by 10 million barrels per day (bpd) - an unprecedented number representing 10% of global supply. Trump said cuts could amount to as much as 15 million bpd but didn't say whether the United States, the world's largest oil producer, would contribute to reductions, a move which is forbidden by U.S. antitrust legislation....
    2 Apr by Vitaliy Dadalyan Tags:

    Walgreens Beats Quarterly Earnings Bets as U.S. Pharmacy Sales Boom

    U.S. drugstore chain operator Walgreens Boots Alliance Inc. (WBA) reported on Thursday second-quarter earnings above analysts’ expectations as consumers stock up on over-the-counter medicine, prescriptions, cleaning and hygiene products.Walgreens said that the impact from the coronavirus pandemic began at the end of the second quarter and was not “material” to overall results. Looking ahead Walgreens cautioned that to date the company was not in a “position to accurately forecast the future impacts.”In the second quarter ended Feb. 29, Walgreens net income fell to $946 million, or $1.07 per share, from $1.16 billion, or $1.24 per share, in the year earlier period. Walgreens posted adjusted EPS of $1.52,  beating the EPS of $1.46 analysts were expecting.Revenue grew to $35.82 billion, from $34.53 billion last year versus the $35.27 billion analysts expected. U.S. retail pharmacy sales rose 3.8% to $27.2 billion in the quarter from the same period a year ago.Wall Street analysts...